Morning Consult today published an opinion piece by the NACDS entitled “DIR Fee Reform: Lining Up Another Win for Patients on Drug Costs.” The op-ed emphasizes the threat of DIR (direct and indirect remuneration) fees and lays out the ways in which DIR fee reform will lower patients’ out-of-pocket costs and reduce overall healthcare costs.
KEY FACTS
- Morning Consult published the op-ed in its Morning Consult Health newsletter.
- DIR fee reform also was a major focus of NACDS RxIMPACT Day on Capitol Hill this week, during which pharmacy advocates from all 50 states reached every Congressional office.
- NACDS is urging the Trump Administration to finalize its proposals to reform DIR fees.
“The amount that Medicare beneficiaries must pay for a prescription drug is supposed to be based on the cost of the drug. However, health plans often calculate patients’ drug prices without subtracting the dollars that the plans claw back from pharmacies many months after the prescription is dispensed. So, patients’ drug costs are artificially inflated, because they are calculated based on an inflated base figure that is more than the plans really pay for drugs. HHS has concluded that eliminating this drug pricing game would reduce patients’ drug costs by an astounding $14.8 billion over 10 years.”
“To summarize, it is simply unsustainable for pharmacies – or for any business – to be undercompensated, often below cost, for goods and services, and for this reimbursement to be completely unpredictable. That is just the beginning of the story, as the unsustainable cycle proceeds from there: higher drug costs, lower medication adherence, diminished patient health, greater reliance on expensive treatments, higher overall healthcare costs.”
